Form 4: Rhythm Pharmaceuticals Director Sells Shares Following RSU Vesting

Christophe Jean, a Director at Rhythm Pharmaceuticals, Inc., disposed of 7,000 common shares on June 18, 2025, following the vesting of 4,000 restricted stock units.

Summary

• Christophe Jean, a Director of Rhythm Pharmaceuticals, Inc. (RYTM), engaged in a stock transaction on June 18, 2025.
• 4,000 Restricted Stock Units (RSUs) held by Mr. Jean fully vested on this date, converting into 4,000 shares of the Issuer's common stock.
• Concurrently, Mr. Jean disposed of 7,000 shares of common stock.
• Following these transactions, Mr. Jean beneficially owns 7,000 shares of Rhythm Pharmaceuticals common stock.
• The disposition of 7,000 shares includes the 4,000 shares acquired from RSU vesting and an additional 3,000 shares previously held, resulting in a net reduction of 3,000 shares in his direct holdings.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there is a net disposition of shares by a director, the transaction includes the routine vesting of RSUs, which is a common compensation event. The net sale of 3,000 shares beyond the RSU vesting is a minor negative, but not indicative of a strong negative sentiment without further context.

Positives

• The vesting of 4,000 Restricted Stock Units (RSUs) indicates a successful compensation event for the director, aligning executive incentives with company performance over time.

Negatives

• The disposition of 7,000 common shares by a director, which represents a net sale of 3,000 shares beyond the RSU vesting, could be perceived as a reduction in insider ownership.
• No specific price for the disposition was disclosed in the filing, which limits the ability to assess the transaction's value.

Risks

• No specific risks related to the company's operations or financial health are detailed in this Form 4 filing, which focuses solely on an insider's stock transaction. However, insider selling, especially a net reduction in holdings, can sometimes be interpreted negatively by the market.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook, as its purpose is solely to report an insider stock transaction.

Industry Context

This filing is a routine insider transaction report specific to Rhythm Pharmaceuticals, Inc. It does not provide information on broader industry trends or competitive landscape. However, insider transactions are closely watched by investors across all industries as an indicator of management's confidence.

Related Party Transactions

• The reported transaction is a related party transaction, as it involves a Director (Christophe Jean) of Rhythm Pharmaceuticals, Inc. disposing of company shares. Specifically, 4,000 Restricted Stock Units vested, and 7,000 common shares were disposed of on June 18, 2025.

Stakeholder Impact

• Shareholders: The net disposition of 3,000 shares by a director could be interpreted by some shareholders as a slight reduction in insider confidence, although it is often a routine part of compensation and liquidity management.

Next Steps

• This Form 4 filing does not specify any future actions, events, or milestones for Rhythm Pharmaceuticals, Inc. or the reporting person beyond the reported transaction.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, Insider Trading, Form 4, Restricted Stock Units, RSU Vesting, Share Disposition, Director Stock Sale, Corporate Governance